Page last updated: 2024-08-16

temozolomide and pazopanib

temozolomide has been researched along with pazopanib in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bozzi, F; Casali, PG; Cominetti, D; Gronchi, A; Libertini, M; Messina, A; Morosi, C; Negri, T; Palassini, E; Pilotti, S; Stacchiotti, S; Tamborini, E; Tortoreto, M; Zaffaroni, N1
Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY1
Bupathi, M; Chen, JL; Hays, JL1
Chawla, S; Chmielowski, B; Dry, SM; Eckardt, MA; Eilber, FC; Higuchi, T; Hoffman, RM; Igarashi, K; Kanaya, F; Kawaguchi, K; Kiyuna, T; Li, Y; Miyake, K; Miyake, M; Murakami, T; Nelson, SD; Oshiro, H; Razmjooei, S; Russell, TA; Singh, AS; Singh, SR; Sugisawa, N; Tome, Y; Wangsiricharoen, S; Zhang, Z; Zhao, M1

Reviews

1 review(s) available for temozolomide and pazopanib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for temozolomide and pazopanib

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Sep-15, Volume: 19, Issue:18

    Topics: Adult; Aged; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Male; Mice; Mice, SCID; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Solitary Fibrous Tumors; Sulfonamides; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays

2013
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
    Journal of the National Cancer Institute, 2013, Nov-20, Volume: 105, Issue:22

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins

2013
Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
    PloS one, 2017, Volume: 12, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Disease Progression; Female; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Temozolomide; Treatment Failure; Vascular Endothelial Growth Factor A; Young Adult

2017
A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model.
    Biochemical and biophysical research communications, 2018, 11-02, Volume: 505, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Fibrosarcoma; Humans; Indazoles; Irinotecan; Male; Mice, Nude; Pyrimidines; Random Allocation; Salmonella Infections; Salmonella typhimurium; Sulfonamides; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays

2018